Etripamil NS 70 mg

DRUG3 trials

Sponsors

Milestone Pharmaceuticals Inc., Corxel Pharmaceuticals

Conditions

Paroxysmal Supraventricular TachycardiaTachycardia, Supraventricular

Phase 3

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

TerminatedNCT03635996

Milestone Pharmaceuticals Inc.Paroxysmal Supraventricular Tachycardia

Start: 2018-12-10End: 2020-11-13Updated: 2024-11-05

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

CompletedNCT04952610

Milestone Pharmaceuticals Inc.Paroxysmal Supraventricular Tachycardia

Start: 2021-12-13End: 2026-04-10Updated: 2026-05-15

Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

CompletedNCT05410860

Corxel PharmaceuticalsParoxysmal Supraventricular Tachycardia, Tachycardia, Supraventricular

Start: 2022-06-30End: 2024-12-10Updated: 2024-12-24

Related Papers

Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study

Journal of the American Heart Association2023-09-2710 citations